Jefferies reiterates Endo at buy

Endo Pharmaceuticals Holdings, Inc. was reiterated at a buy with a new price target of $36 by Jefferies & Co., Inc. analyst David Windley as the company prepares to launch Opana in the next few weeks. Opana is expected to be one of the company's largest franchises. Jefferies raised its 2007 earnings-per-share estimates by 5 cents to $1.97 and lowered its 2006 earnings per share by 20 cents. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up 31 cents, or 0.98%, at $31.81 on volume of 2,958,874 shares versus the three-month running average of 1,151,270 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.